Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.
Tavakoli
Sirpa A
SA
Arguisola
Maria S
MS
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy*; D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000175:diagnosis; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced / Q000175:diagnosis; D016883:Diabetic Ketoacidosis / Q000139:chemically induced* / Q000175:diagnosis; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009765:Obesity; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
D000927:Anticonvulsants; D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D003511:Cyclohexanols; D001569:Benzodiazepines; D010890:Pirenzepine; D014635:Valproic Acid; D000069470:Venlafaxine Hydrochloride; D000077152:Olanzapine